This invention is directed to a method of enhancing or facilitating the clearance or the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the hydration of the lung mucus secretions in a subject. This invention is further directed to a method of preventing or treating diseases or conditions associated with impaired lung or airway function in a human or other mammal. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y 6 receptor agonist compound, wherein said amount is effective to activate the P2Y 6 receptors on the luminal surface of lung epithelia. The P2Y 6 receptor agonist compounds useful for this invention include mononucleoside 5′-diphosphates, dinucleoside monophosphate, dinucleoside diphosphates, or dinucleoside triphosphates of general Formula I, or salts, solvates, hydrates thereof. This invention is also directed to novel P2Y 6 receptor agonist compounds.
1. A compound selected from the group consisting of: P 1 -(2′,3′-phenylacetal uridine 5′-)P 3 -(uridine 5′-)triphosphate; P 1 -[2′,3′-(phenylacetylene)acetal uridine 5′-]P 3 -(uridine 5′)triphosphate; P 1 -(2′,3′-phenylacetal cytidine 5′-)P 3 -(uridine 5′-)triphosphate, and P 1 -(2′,3′-benzylacetal guanosine 5′-)P 3 -(uridine 5′-)triphosphate.
2. The compound according to claim 1 , which is P 1 -(2′,3′-phenylacetal uridine 5′-)P 3 -(uridine 5′-)triphosphate.
3. The compound according to claim 1 , which is P 1 -[2′,3′-(phenylacetylene)acetal uridine 5′-]P 3 -(uridine 5′-)triphosphate.
4. The compound according to claim 1 , which is P 1 -(2′,3′-phenylacetal cytidine 5′-)P 3 -(uridine 5′-)triphosphate.
5. The compound according to claim 1 , which is P 1 -(2′,3′-benzylacetal guanosine 5′-)P 3 -(uridine 5′-)triphosphate.